Dr Simone De Luca recently received the 2020 CANTAB Research Grant primary award for her project: “New ways to assess vascular cognitive impairment and dementia (VCID) in chronic lung disease”. We spoke to her about the impact winning would have on her research.
Alexander Friend shares the role CANTAB played in the research he conducted on cognitive impairment at high-altitude while at The University of Birmingham.
Older adults are consistently under-represented in clinical trials, even though they take more prescription medications than any other group. In this two part series, Dr Kiri Granger will explore this under-presentation and outline practical considerations for including older adults in clinical trials.
Read on for session one: the importance of addressing the evidence-practice gap.
NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly to patients through mobile and tele-health platforms, helping to improve outcomes in clinical trials, aid clinical decision-making and play an important role in the management of long-term conditions such as chronic pain.
Healthy Amplified are using CANTAB® technology to expand their population health platform offering to adults.
We caught up with brain health and workplace mental performance consultant, Dr Jenny Brockis, on how tools like CANTAB BrainHealth can be used to promote mental wellbeing at work.
We are very pleased to announce a planned new software product to assess mental health and wellbeing at work, CANTAB BrainHealth™.
Mental and substance use disorders are now the leading cause of disability worldwide, resulting in 23% of all years lost with a global economic loss of a trillion US dollars every year1 which is why we are very pleased to announce a new strategic collaboration and partnership with the University of Bristol to accelerate the development of novel brain health products.
At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.
Cambridge Cognition is attending the Alzheimer's Association International Conference in London.
Winner of the 2016 Global Prize for the CANTAB Research Grant, Toni McCrossin, Clinical Officer for the New South Wales Brain Tissue Resource Centre (NSWBTRC) explains how access to CANTAB cognitive assessments are supporting their project.
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition looks at how digital innovations are helping our brain health.
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition examines the power that digital innovation has to change the way we look at brain health.
Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)
Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition reviews how the rise of touchscreen technology has enabled the expansion of cognitive assessment.